J B Chemicals & Pharmaceuticals, which sold its Russia-CIS OTC business in July 2011, has registered net sales growth of 31.9 per cent during the second quarter ended September 2012 to Rs. 212.12 crore as compared to Rs. 160.77 crore in the corresponding period of last year. Its other operating income declined to Rs. 5.12 crore from Rs. 32.88 crore, which impacted its profit level. The EBDITA declined by 18.3 per cent to Rs. 46.89 crore from Rs. 57.38 crore. The figures are not strictly comparable as the company sold its OTC business in the previous period and it provided Rs. 760.59 crore as exceptional item in the last period. The net profit worked out to Rs. 39 crore for the quarter under review.

For the first half ended September 2012, its net sales increased by 17.4 per cent to Rs. 396.97 crore from Rs. 338.22 crore. However, its EBDITA declined by 16.8 per cent to Rs. 78.53 crore from Rs. 94.39 crore in the similar half of last year. The net profit stated at Rs. 43.31 crore.